Long-Term Effectiveness and Safety Evaluation of Ocrelizumab in French Patients with Progressive MS: Consonance Extension Study

2024-516433-13-00 Protocol 21-PP-23 Therapeutic confirmatory (Phase III) Authorised, recruiting

Start 19 Sep 2024 · Status Authorised, recruiting · 1 EU/EEA countries · 15 sites · Protocol 21-PP-23

Overview

Sponsor-declared trial summary

Phase Therapeutic confirmatory (Phase III)
Status Authorised, recruiting
Participants planned 89
Countries 1
Sites 15

Progressive multiple sclerosis

Key facts

Sponsor
Centre Hospitalier Universitaire De Nice
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
19 Sep 2024 → ongoing
Decision date (initial)
2024-09-19
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516433-13-00
EudraCT number
2021-006107-15

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Progressive multiple sclerosis

VersionLevelCodeTermSystem organ class
20.0 HLT 10052785 Multiple sclerosis acute and progressive 10029205

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire De Nice

Sponsor organisation
Centre Hospitalier Universitaire De Nice
Address
4 Avenue Reine Victoria
City
Nice
Postcode
06000
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire De Nice
Contact name
Pr LEBRUN-FRENAY

Public contact point

Organisation
Centre Hospitalier Universitaire De Nice
Contact name
Mélanie Bonnard

Locations

1 EU/EEA country · 15 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Authorised, recruiting 89 15
Rest of world 0

Investigational sites

France

15 sites · Authorised, recruiting
Centre Hospitalier Regional De Marseille
Neurology, 144 Rue Saint Pierre, 13005, Marseille
Centre Hospitalier Universitaire De Caen Normandie
Neurology, Avenue De La Cote De Nacre, Cs 30001, Caen Cedex 9
CHU Amiens - Groupe Hospitalier Sud
Neurology, 1 1 rond-point du Professeur Cabrol, 80054, AMIENS
Les Hopitaux Universitaires De Strasbourg
Neuropogy, 1 Avenue Moliere, Bp 49, Strasbourg Cedex 2
Centre Hospitalier De La Cote Basque
neurology, 13 Avenue Interne Jacques Loeb, 64100, Bayonne
Centre Hospitalier Universitaire De Nimes
Neurology, Place Du Professeur Robert Debre, 30900, Nimes
Centre Hospitalier Universitaire De Montpellier
Neurology, 191 Avenue Du Doyen Gaston Giraud, 34295, Montpellier Cedex 5
CHU de Nantes - Hôpital Laennec
Neurology, Boulevard Jacques Monod, 44093, Nantes Cedex 1
CHRU De Nancy
neurology, 29 Avenue Du Mal De Lattre De Tassigny, 54000, Nancy
Centre Hospitalier Universitaire De Lille
Neurology, 2 Avenue Oscar Lambret, Cs 70001, Lille Cedex
Centre Hospitalier Universitaire De Bordeaux
Neurology, Place Amelie Raba Leon, 33000, Bordeaux
Centre Hospitalier Universitaire De Rennes
Neurology, 2 Rue Henri Le Guilloux, 35000, Rennes
CHU Gabriel-Montpied
Neurology, 58 Rue Montalembert, 63000, Clermont Ferrand
Hospices Civils De Lyon
Neurology, 59 Boulevard Pinel, 69500, Bron
Centre Hospitalier Universitaire De Nice
Neurology, 30 Voie Romaine, 06000, Nice

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-09-19

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-26 France Acceptable
2024-09-16
2024-09-19
2 SUBSTANTIAL MODIFICATION SM-1 2025-07-28 France Acceptable
2025-09-30
2025-10-02